| DC67194 |
(5-pyrrolidin-1-ylsulfonyl-2-furyl)methanamine
Featured
|
|
|
| DC67195 |
N-(2-aminoethyl)-5-chlorothiophene-2-sulfonamide
Featured
|
|
|
| DC67196 |
phenyl 2,5-Dichloro-3-Thienyl Sulfone
Featured
|
|
|
| A817 |
Zolbetuximab
Featured
|
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. |
|
| A818 |
DS-9606A
Featured
|
DS-9606A is a humanized antibody expressed in CHO cells, targeting CLDN6. DS-9606A features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for DS-9606A can refer to Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A819 |
Anti-CLDN6 Reference Antibody (64A)
Featured
|
|
|
| A820 |
Anti-CLDN6 Antibody (AB3-7)
Featured
|
|
|
| A821 |
Anti-CLDN6 Reference Antibody (AE3-20)
Featured
|
|
|
| A822 |
Anti-CLDN6 Reference Antibody (IM-302)
Featured
|
|
|
| A823 |
Tepoditamab
Featured
|
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. |
|
| A824 |
Scripps Korea patent anti-CLEC14A
Featured
|
|
|
| A825 |
Litifilimab
Featured
|
Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study. |
|
| A826 |
LFB patent anti-BDCA-2
Featured
|
|
|
| A827 |
Baylor patent anti-Dectin-1
Featured
|
|
|
| A828 |
Sotevtamab
Featured
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research. |
|
| A829 |
Empasiprubart
Featured
|
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models. |
|
| A830 |
NGM-621
Featured
|
|
|
| A831 |
Crovalimab
Featured
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research. |
|
| A832 |
Pozelimab
Featured
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases. |
|
| A833 |
Ravulizumab
Featured
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. |
|
| A834 |
Vilobelimab
Featured
|
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc. |
|
| A835 |
Avdoralimab
Featured
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research. |
|
| A836 |
G2 patent anti-C5aR
Featured
|
|
|
| A837 |
G2_anti-C5aR
Featured
|
|
|
| A838 |
Genentech patent anti-Factor B
Featured
|
|
|
| A839 |
Lampalizumab
Featured
|
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. |
|
| A840 |
Novelmed patent anti-Properdin
Featured
|
|
|
| A841 |
Regeneron patent anti-RET
Featured
|
|
|
| A842 |
Oxford Bio patent anti-CRTAM
Featured
|
|
|
| A843 |
Cabiralizumab
Featured
|
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research. |
|
